The Australian Peptide Research Landscape 2026

A comprehensive reference mapping Australian peptide research in 2026: TGA regulatory framework, major peptide classes, research institutions, compounding rules, and 2024–26 policy shifts.

Australia occupies an unusual position in the global peptide research environment. It operates one of the world's more granular regulatory classification systems — the Poisons Standard, administered by the Therapeutic Goods Administration — while simultaneously hosting several research institutions at the frontier of peptide pharmacology, metabolic medicine, and longevity biology. The 2024–25 period brought the most significant regulatory activity in the peptide space in a decade, centred on compounded GLP-1 agonists but with implications extending across the broader research-peptide category.

This reference maps the Australian peptide research landscape as it stands in 2026: the regulatory architecture, the major research classes and their evidence bases, the institutions conducting relevant work, the practical distinctions between compounded and research-grade access, the policy shifts of 2024–26, and the outlook for the near term. It is intended as a stable reference for researchers, clinicians, policy writers, and regulators navigating an environment that has changed substantially in a short period.

For foundational background on peptide categories and mechanisms, see the research peptides complete guide. For the Khavinson bioregulator framework specifically, see the peptide bioregulators overview.

Regulatory framework

The Poisons Standard and schedule architecture

The regulatory status of any peptide in Australia is determined principally by its classification in the Poisons Standard — formally the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP), made under the Therapeutic Goods Act 1989. The TGA publishes and periodically amends the Poisons Standard; the current consolidated instrument is available at the Federal Register of Legislation.

Schedule 4 (Prescription Only Medicine): Peptides classified as Schedule 4 require a valid prescription from an authorised prescriber. This schedule covers the approved GLP-1 receptor agonists (semaglutide as Ozempic/Wegovy; liraglutide as Saxenda/Victoza; dulaglutide as Trulicity) and growth hormone (somatropin). Schedule 4 status means these compounds can legally be prescribed and dispensed through the normal pharmaceutical supply chain, but prohibits supply without prescription.

Schedule 10 (Prohibited Substances): Schedule 10 classification represents the most restrictive tier — substances where the risks are considered to outweigh any therapeutic benefit, and which are prohibited from sale, supply, or use except in specifically exempted circumstances (primarily analytical reference standards). Several peptides of research interest, including some anabolic compounds, sit in or near this schedule. No currently prominent research peptides (BPC-157, CJC-1295, epithalon, MOTS-c) are Schedule 10.

Unscheduled compounds: Many peptides with active research programs — including most of the compounds discussed in this reference — are not currently listed in the Poisons Standard. Unscheduled status does not imply approval for therapeutic use; it means the compound has not yet been evaluated for scheduling by the TGA or has been assessed and not placed in a schedule. Supply of unscheduled substances for human therapeutic use may still be regulated under the broader provisions of the Therapeutic Goods Act if the substance is presented as, or used as, a medicine.

The current Poisons Standard is maintained at: https://www.tga.gov.au/resources/resource/guidance/poisons-standard-susmp

The 2024–25 compounded GLP-1 enforcement action

The most consequential regulatory event of the 2024–25 period was the TGA's enforcement action against compounded semaglutide and tirzepatide. In August 2024, the TGA issued a notice advising that compounding pharmacies could not prepare medicines that are bioequivalent to, or that substitute for, currently marketed therapeutic goods — specifically targeting compounded semaglutide products that were being marketed as alternatives to Ozempic and Wegovy during the supply shortage period.

The TGA's formal position, outlined in its August 2024 media release, was that compounded semaglutide posed patient safety risks related to dosing accuracy, sterility, and the use of unapproved salt forms (particularly semaglutide sodium rather than the free acid form used in approved products). The enforcement notice directed compounders to cease supply of these products. A subsequent period of compliance activity followed through late 2024 and into 2025.

The TGA media release on compounded semaglutide enforcement (August 2024) is available at: https://www.tga.gov.au/news/media-releases/tga-takes-action-compounded-semaglutide

Notice of Compliance and therapeutic goods registration

For a peptide to be legally supplied as a therapeutic good in Australia, it must be entered on the Australian Register of Therapeutic Goods (ARTG) — either as a Registered medicine (evaluated by the TGA for quality, safety, and efficacy) or as a Listed medicine (self-assessed against a list of permitted ingredients). Peptides with pharmacological activity invariably require registration rather than listing.

The registration pathway involves submission of a dossier to the TGA, including preclinical pharmacology data, clinical trial data (typically Phase I–III), pharmaceutical quality data, and a risk management plan. The TGA evaluates against international standards and typically aligns with decisions made by the EMA and FDA, though it conducts independent review. Approval timelines for novel compounds run 12–18 months from complete submission under standard evaluation, or 6 months under priority review for conditions with unmet need.

AHPRA practitioner guidance

The Australian Health Practitioner Regulation Agency (AHPRA) regulates health practitioners across 16 registered professions. AHPRA has issued guidance relevant to peptide prescribing in several contexts, most directly through the Medical Board of Australia's guidance on prescribing and through joint statements on compounded medications.

The Medical Board's prescribing guidelines require that prescribing be within the practitioner's scope of competence and be clinically justified for the individual patient. Prescribing unapproved therapeutic goods — including research peptides — requires specific authority and is tightly constrained. Prescribers who prescribe outside approved indications or prescribe unapproved compounds without appropriate authority face potential AHPRA regulatory action.

AHPRA practitioner registration standards and guidance are available at: https://www.ahpra.gov.au/Registration/Registration-Standards.aspx

Clinical trial pathway: the CTN scheme

The primary regulatory pathway for human clinical research on unregistered therapeutic goods in Australia is the Clinical Trial Notification (CTN) scheme, administered under the Therapeutic Goods Act. The CTN scheme allows clinical trials involving unapproved therapeutic goods to proceed after notification to the TGA (rather than requiring TGA pre-approval), provided the trial has been approved by a Human Research Ethics Committee (HREC) accredited under the National Health and Medical Research Council framework.

The CTN scheme is administratively lighter than a full IND application (the US equivalent) and has been a significant factor in making Australia an attractive location for early-phase clinical trial work, particularly for international sponsors seeking efficient Phase I and Phase II capacity. Australia also operates the Clinical Trial Exemption (CTX) scheme for situations where TGA pre-evaluation of the trial protocol is desired, though CTX is less commonly used.

The TGA's clinical trial framework is documented at: https://www.tga.gov.au/how-we-regulate/clinical-trials

Major peptide research classes

Metabolic / GLP-1 receptor agonists

| Compound | Class | Approval status (Australia) | Trial phase (globally) | |---|---|---|---| | Semaglutide | GLP-1 agonist | TGA-registered (Ozempic, Wegovy) | Approved; multiple extension trials | | Tirzepatide | GLP-1/GIP dual agonist | TGA-registered (Mounjaro) | Approved; SURMOUNT extension trials | | Retatrutide | GLP-1/GIP/glucagon triple agonist | Not registered | Phase II completed | | Orforglipron | Non-peptide GLP-1 agonist | Not registered | Phase III | | Cagrilintide | Amylin/GLP-1 combination | Not registered | Phase III (CagriSema) |

Mechanism: GLP-1 receptor agonists act through three convergent mechanisms: glucose-dependent insulinotropism at pancreatic beta cells, gastric emptying delay via vagal afferent GLP-1 receptors, and central appetite suppression through hypothalamic GLP-1R. The dual and triple agonists extend this by adding GIP receptor (which amplifies insulin secretion and may have direct adipose effects) and glucagon receptor (which increases energy expenditure) engagement. For detailed mechanistic coverage, see GLP-1 receptor agonists explained.

Current evidence: The GLP-1 class has the strongest clinical evidence base of any research peptide category. The SUSTAIN and STEP trial series for semaglutide demonstrated 10–15% body weight reduction over 68 weeks in the STEP 1 trial (Wilding et al., 2021, NEJM: https://pubmed.ncbi.nlm.nih.gov/33567185/). The SURMOUNT-1 trial for tirzepatide demonstrated up to 20.9% weight reduction at the highest dose (Jastreboff et al., 2022, NEJM: https://pubmed.ncbi.nlm.nih.gov/35658024/). Retatrutide Phase II data (Jastreboff et al., 2023, NEJM) showed up to 24.2% weight loss — the highest reported for any pharmacological intervention in a randomised trial at the time of publication. Cardiovascular outcome data from LEADER (liraglutide) and SELECT (semaglutide) confirm significant MACE reduction in high-risk populations; the GLP-1 cardiovascular outcomes article covers this evidence in detail.

Australian regulatory status: Semaglutide and tirzepatide are TGA-registered. Novel agents in this class — retatrutide, orforglipron, cagrilintide — are not registered and are not legally available as therapeutic goods in Australia. Clinical research access is possible via the CTN scheme with HREC approval.

Notable Australian context: Australian investigators participate in global GLP-1 trial programs as site investigators. Monash University's Obesity and Metabolic Disease Unit and the Royal Melbourne Hospital's Department of Endocrinology have been active in GLP-1 pharmacology research.

Bioregulators (Khavinson peptides)

| Peptide | Source tissue | Primary studied effect | Evidence level | |---|---|---|---| | Epithalon (Epitalon) | Pineal | Telomerase activation, melatonin modulation | Preclinical + limited clinical | | Thymalin | Thymus | Immune senescence, T-cell function | Clinical (Russian cohort studies) | | Cortagen | Cerebral cortex | Neuronal gene expression | Preclinical | | Pinealon | Pineal | Neuroprotection, circadian | Preclinical | | Cardiogen | Cardiac tissue | Cardiomyocyte gene expression | Preclinical |

Mechanism: The Khavinson bioregulator framework proposes that short di- to tetrapeptides derived from tissue extracts modulate gene expression by interacting with chromatin-associated histone proteins, altering transcription factor access at specific gene promoters. The mechanism is intranuclear rather than receptor-mediated — a fundamentally different pharmacological category from most peptide compounds. The peptide bioregulators overview provides full mechanistic detail including the chromatin interaction hypothesis.

Current evidence: The bioregulator literature is extensively published but heavily concentrated in Russian-language journals and the St. Petersburg Institute of Bioregulation and Gerontology group. Independent replication is limited. The strongest replicated data concern epithalon's telomerase activation in cell culture (confirmed by several independent groups) and rodent longevity studies. A 2003 review by Khavinson in Neuro Endocrinology Letters covering pineal and thymic peptide bioregulators and their reported longevity effects: https://pubmed.ncbi.nlm.nih.gov/14523363/. No bioregulator peptide has completed a large randomised controlled trial meeting ICH GCP standards with independent oversight.

Australian regulatory status: Bioregulator peptides are not listed in the Poisons Standard and are not registered on the ARTG. Their unscheduled status means supply for human therapeutic use without registration would be in breach of the Therapeutic Goods Act. Research use via CTN with HREC approval is theoretically available but no Australian trials are registered on ANZCTR for these compounds as of early 2026.

Growth-hormone secretagogues

| Compound | Mechanism | Regulatory status (AU) | Evidence | |---|---|---|---| | CJC-1295 | GHRH analogue | Not scheduled | Preclinical + small clinical | | Ipamorelin | Ghrelin/GHSR agonist | Not scheduled | Preclinical + small clinical | | Tesamorelin | GHRH analogue | Not registered (TGA) | FDA-approved (Egrifta) for HIV lipodystrophy |

Mechanism and evidence: GH secretagogues work upstream of growth hormone itself, stimulating GH release from the pituitary either by mimicking GHRH (CJC-1295, tesamorelin) or by activating the ghrelin receptor (ipamorelin). The result is a pulsatile GH release pattern — more physiologically similar to endogenous GH dynamics than direct GH administration. This is pharmacologically important: pulsatile GH release preserves IGF-1 feedback regulation and reduces the risk of tachyphylaxis and GH-mediated insulin resistance that accompany continuous GH elevation. The growth hormone secretagogues science article covers the mechanistic comparison in detail.

Tesamorelin has the strongest clinical evidence — it is FDA-approved for HIV-associated lipodystrophy (registered trial NCT00119717 at ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT00119717) — but is not TGA-registered in Australia. CJC-1295 and ipamorelin have small clinical datasets but no large RCT evidence. Their use in combination is common in research protocols on the basis of complementary receptor mechanisms, though this combination has not been formally studied in a powered clinical trial.

Australian regulatory status: GH secretagogues are not scheduled in the Poisons Standard (as of early 2026) but are in a regulatory grey zone under the Therapeutic Goods Act when supplied with therapeutic intent. The TGA has flagged this category in its monitoring of online supply of performance-enhancing substances.

Tissue repair peptides

| Compound | Primary mechanism | Evidence level | |---|---|---| | BPC-157 | Nitric oxide modulation, growth factor upregulation | Extensive preclinical; no RCT | | TB-500 (Thymosin beta-4) | Actin sequestration, angiogenesis | Preclinical + Phase II (cardiac) |

BPC-157: Body protection compound-157 is a 15-amino acid synthetic peptide derived from a gastroprotective sequence in gastric juice. Extensive rodent data — hundreds of published studies — document accelerated healing in tendon, ligament, muscle, and gastrointestinal tissues, with proposed mechanisms including nitric oxide synthase upregulation, VEGF-mediated angiogenesis, and growth factor receptor modulation. The rodent literature is unusually consistent across independent groups. No published randomised controlled trial in humans exists as of 2026. The absence of human trial data is the central evidentiary gap. It is unscheduled in Australia.

TB-500 / Thymosin beta-4: Thymosin beta-4 is an endogenous 43-amino acid peptide involved in actin polymerisation dynamics, with demonstrated roles in wound healing, angiogenesis, and cardiac regeneration. It has progressed to human trials in the cardiac context — a Phase II trial in patients with pressure overload heart failure was registered at ClinicalTrials.gov (NCT01311518: https://clinicaltrials.gov/study/NCT01311518). TB-500 is a synthetic fragment (Ac-SDKP) rather than the full peptide. It is unscheduled in Australia.

Mitochondrial peptides

| Peptide | Encoded in | Primary signalling role | |---|---|---| | MOTS-c | 12S rRNA (mtDNA) | Skeletal muscle insulin sensitivity, metabolic stress response | | SS-31 (Elamipretide) | Synthetic | Cardiolipin stabilisation, mitochondrial membrane integrity | | Humanin | 16S rRNA (mtDNA) | Cytoprotection, anti-apoptotic, neuroprotection |

Mechanism: MOTS-c and humanin are mitochondrial-derived peptides (MDPs) — encoded within the mitochondrial genome and released systemically as mitokines that signal the cellular metabolic state to distant tissues. MOTS-c has been the subject of a growing rodent literature showing insulin sensitisation in skeletal muscle and exercise-mimetic metabolic effects. A Phase I safety trial for MOTS-c (NCT04224701) is registered at ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT04224701. SS-31 (elamipretide) is a synthetic tetrapeptide that targets cardiolipin on the inner mitochondrial membrane, stabilising electron transport chain complexes. It has completed Phase II trials in Barth syndrome and heart failure. Full mechanistic coverage is in the mitochondrial peptides research overview.

Australian regulatory status: All three are unscheduled. No Australian ANZCTR trials for these specific MDPs were registered as of early 2026. SS-31/elamipretide is the furthest along the global clinical trial pipeline and the most likely to reach ARTG registration if Phase III data support approval.

Nootropic peptides

| Compound | Origin | Proposed mechanism | Clinical status | |---|---|---|---| | Semax | Synthetic ACTH fragment | BDNF upregulation, neuroprotection | Registered in Russia; no Phase III in West | | Selank | Synthetic tuftsin analogue | Anxiolytic, GABA modulation | Registered in Russia; no Western RCT | | Noopept | Synthetic dipeptide | GluR sensitisation, NGF/BDNF modulation | Unregistered globally | | Dihexa | Hepatocyte growth factor modulator | HGF/c-Met potentiation, synaptogenesis | Preclinical only |

Mechanism and evidence: The nootropic peptide category encompasses compounds that modulate central nervous system function — primarily through neurotrophic factor upregulation, GABAergic modulation, or glutamatergic receptor sensitisation. Semax (ACTH(4-10) analogue) has the largest body of published clinical data — it is registered in Russia and Ukraine for stroke and cognitive impairment indications — but this data does not meet the evidentiary standards required for Western regulatory approval (independent randomisation, blinding, and pre-specified primary endpoints). Selank, similarly registered in Russia as an anxiolytic, lacks randomised controlled trial data that would satisfy ICH E9 requirements. Dihexa has an interesting mechanistic profile (it potentiates hepatocyte growth factor binding to c-Met, with downstream synaptogenesis) but remains preclinical only, with no published human data.

Australian regulatory status: None of the compounds in this category are scheduled in the Poisons Standard or registered on the ARTG. Their legal status for supply in Australia mirrors that of other unscheduled research compounds.

Notable Australian research institutions

Australian peptide and metabolic research is distributed across several major universities and research institutes. The following are publicly known research groups with relevance to the peptide landscape:

Monash University — Biomedicine Discovery Institute (BDI): The BDI houses research programs in peptide pharmacology, GPCR biology, and structural characterisation of peptide-receptor interactions. The Monash Institute of Pharmaceutical Sciences (MIPS) has published on peptide drug design and GLP-1 receptor structure. The BDI's cryo-EM facility has contributed to structural characterisation of class B GPCRs including the GLP-1 receptor, with implications for novel agonist design.

University of Queensland — Institute for Molecular Bioscience (IMB): The IMB has a strong track record in peptide discovery, including cone snail venom peptide pharmacology (conotoxins) and other naturally derived peptide compounds. UQ researchers contributed to the characterisation of ziconotide (an approved conotoxin-derived analgesic), one of Australia's most significant contributions to peptide therapeutics. The IMB also houses the Centre for Advanced Imaging for structural biology work.

Walter and Eliza Hall Institute of Medical Research (WEHI): WEHI has a peptide and protein chemistry program relevant to immunological peptides and signalling peptides, including stapled peptide technology for intracellular target engagement. WEHI researchers have published on BH3 mimetic peptide development and apoptosis regulation.

Garvan Institute of Medical Research: Garvan's Diabetes and Metabolism Division maintains active research in incretin biology, GLP-1 pharmacology, and the metabolic consequences of obesity. Garvan researchers have participated in clinical investigation of approved GLP-1 agents and have published mechanistic work on beta cell function and insulin secretion dynamics.

University of Melbourne — Department of Biochemistry and Pharmacology: Research groups here have published on peptide-GPCR interactions and signalling bias — relevant to the pharmacological understanding of GLP-1 agonist class effects versus side effects.

RMIT University — School of Science: RMIT's research in the peptide space includes bioactive peptide discovery from food proteins and structural characterisation of short peptide compounds — methodologically relevant to the bioregulator research area.

The Australian Institute of Sport (AIS): While not a peptide research institute per se, the AIS maintains an active program on substance monitoring relevant to GH secretagogues and peptides on the WADA prohibited list. The AIS contributes to anti-doping analytical method development that intersects with the GH secretagogue and peptide detection literature.

Compounded versus research-grade access

Compounding pharmacy rules in Australia

Compounding — the preparation of a medicine by a pharmacist for a specific patient under the direction of a prescriber — is regulated under the Therapeutic Goods Act and state/territory pharmacy legislation. The central principle is that compounding is lawful when a registered therapeutic good is not commercially available in the strength, form, or combination required for a specific patient's needs.

The TGA's compounding framework distinguishes between:

Non-registered compounding: Preparation of medicines using ingredients that are not registered therapeutic goods. This is permitted in specific circumstances — primarily where a therapeutic need exists and the formulation cannot be met by registered products — and requires that ingredients meet appropriate quality standards.
Registered-equivalent compounding: Preparation of medicines that are bioequivalent to, or substitute for, currently registered products. This is the category that the 2024 enforcement action addressed — specifically that compounded semaglutide was being substituted for registered Ozempic/Wegovy.

The key regulatory instrument is the TGA's guidance on therapeutic goods legislation and pharmacy compounding, which specifies permitted circumstances. As of 2025, compounding pharmacies cannot legally prepare compounded versions of currently marketed Schedule 4 peptide therapeutics (semaglutide, tirzepatide, liraglutide) unless a genuine documented clinical reason — such as allergy to an excipient in the registered product — justifies the compounded preparation for an individual patient.

Research-use versus therapeutic-use distinctions

The regulatory distinction between research use and therapeutic use of peptides is significant in Australian law. Under the Therapeutic Goods Act, a substance is regulated as a therapeutic good when it is "for use in... preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury in persons" — the intended use, not the chemical nature of the substance, triggers the Act's operation.

A peptide compound acquired for genuine laboratory research — characterisation of receptor binding, in vitro cell culture work, analytical method development — is not regulated as a therapeutic good and falls outside the Therapeutic Goods Act's therapeutic goods provisions (though it may be subject to other legislation including the Customs Act and state/territory dangerous goods legislation). The same compound acquired or supplied with intent that it be administered to humans for a therapeutic purpose is regulated as a therapeutic good, regardless of whether it is labelled "for research use only."

This distinction is why the "research use only" labelling common on peptide supply websites does not confer legal protection when the supply model is clearly oriented toward human use. The TGA has stated this position in guidance and has taken action against suppliers on this basis.

2024–26 policy shifts

August 2024 — Compounded GLP-1 enforcement: As described above, the TGA directed compounders to cease supply of compounded semaglutide. This action resolved a tension that had developed during the Ozempic supply shortage of 2022–23, when many compounders had stepped in to fill supply gaps. The shortage is no longer the basis for an exemption, and the TGA's position is that compounded semaglutide supply was never appropriately authorised under the compounding provisions even during shortage conditions.

2024–25 — AHPRA escalation on prescriber conduct: The Medical Board of Australia and AHPRA issued updated guidance in 2024 on prescribing for weight management, responding to concerns about telehealth-mediated prescribing of GLP-1 agents outside appropriate clinical assessment frameworks. The guidance emphasised that prescribers must conduct or have access to adequate clinical information (including comorbidity assessment, contraindication screening, and baseline measurements) before initiating GLP-1 therapy, and that prescribing on the basis of patient self-report through brief online consultations may not meet this standard.

2025 — Scheduling review of GH secretagogues: The TGA convened a Scheduling Delegate's interim decision process to consider whether GH secretagogues (CJC-1295, ipamorelin, and related compounds) should be added to the Poisons Standard. As of early 2026, final decisions had not been published, but the review signals increasing TGA attention to this compound class. Stakeholders in the research and medical communities submitted responses to the consultation.

2025 — Australian Register update for tirzepatide: Mounjaro (tirzepatide) received ARTG listing for weight management in addition to its earlier type 2 diabetes listing, expanding the prescribing population. This followed the Therapeutic Goods Committee's review of the SURMOUNT trial data and aligned Australia with regulatory decisions already made by the FDA and EMA.

Ongoing — Anti-doping intersection: The World Anti-Doping Agency (WADA) prohibited list includes multiple peptide hormones and GH secretagogues. The Australian Sports Anti-Doping Authority (ASADA) enforces WADA standards in Australian sport. The intersection between the research peptide landscape and anti-doping regulation creates compliance complexity for practitioners treating both recreational and competitive athlete populations.

Outlook 2027

Several trends are likely to shape the Australian peptide research environment over the next 12–24 months:

GLP-1 class expansion: Retatrutide (triple agonist) and orforglipron (oral non-peptide GLP-1 agonist) are both in Phase III globally. If Phase III data support approval — and early signals for both are positive — TGA registration applications could be filed in 2026–27. Retatrutide's 24% weight loss signal would represent a step change from current approved agents; orforglipron's oral bioavailability removes the injection barrier that limits uptake of current approved agents. Australia's regulatory alignment with FDA/EMA decisions means local approval timelines would likely lag global approval by 12–24 months.

GH secretagogue scheduling decision: The TGA's scheduling review of CJC-1295, ipamorelin, and related compounds is likely to conclude in 2026. A decision to schedule these compounds as Schedule 4 would substantially change their supply landscape — moving them from effectively unregulated supply to requiring prescriptions. A decision not to schedule would not resolve the therapeutic-use supply question under the Therapeutic Goods Act's broader provisions.

Compounding landscape consolidation: The 2024 enforcement action created significant uncertainty for compounding pharmacies that had built business models around peptide compounding. The medium-term outlook is for further consolidation and contraction of compounding supply of peptides, as pharmacies assess legal risk. This will likely increase the proportion of peptide access occurring through less-regulated channels — a public health outcome the TGA is presumably aware of.

Research infrastructure: Australia's clinical trial environment remains internationally competitive due to the CTN scheme, the 43.5% R&D tax incentive for trial expenditure (available to international sponsors), and the quality of HREC review capacity. Peptide trials — particularly in the metabolic and longevity space — may increase as global sponsors seek efficient Phase I/II sites. The Monash BDI and UQ IMB structural biology infrastructure supports compound characterisation work that underpins drug design programs.

Bioregulator evidence gap: The bioregulator peptide class (epithalon, thymalin, and the broader Khavinson series) faces an evidence gap that is unlikely to close quickly. No major trial program is registered in Australia or internationally. Independent replication of the chromatin interaction mechanism — which would require sophisticated ChIP-seq or ATAC-seq studies in human cell models — has not materialised at scale. This category will likely remain in a holding pattern: preclinical data available, independent characterisation incomplete, clinical trial data absent.

Mitochondrial peptide translation: SS-31 (elamipretide) is the most likely of the mitochondrial-derived peptides to achieve clinical translation in the near term, given its Phase II trial data in Barth syndrome. Global regulatory decisions on elamipretide — if they occur in 2026–27 — could motivate TGA applications for Australian registration, opening a compounding and specialist prescribing pathway for the first time for a mitochondrial-targeted peptide.

Primary sources and further reading

TGA — Poisons Standard (current instrument): https://www.tga.gov.au/resources/resource/guidance/poisons-standard-susmp — Authoritative source for current schedule classification of all substances including peptides.
TGA — Compounded semaglutide enforcement (August 2024): https://www.tga.gov.au/news/media-releases/tga-takes-action-compounded-semaglutide — Formal regulatory position on compounded GLP-1 supply.
TGA — Clinical trials framework (CTN/CTX schemes): https://www.tga.gov.au/how-we-regulate/clinical-trials — Regulatory pathway for human research on unapproved therapeutic goods.
Wilding et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. NEJM. PMID 33567185: https://pubmed.ncbi.nlm.nih.gov/33567185/ — STEP 1 trial: primary efficacy evidence for semaglutide in weight management.
Jastreboff et al. (2022). Tirzepatide once weekly for the treatment of obesity. NEJM. PMID 35658024: https://pubmed.ncbi.nlm.nih.gov/35658024/ — SURMOUNT-1 trial: primary efficacy evidence for tirzepatide.
Khavinson VKh (2003). Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters 24(3-4):233–240. PMID 14523363: https://pubmed.ncbi.nlm.nih.gov/14523363/ — Overview publication from Khavinson group on bioregulator peptide framework.
ClinicalTrials.gov — MOTS-c Phase I (NCT04224701): https://clinicaltrials.gov/study/NCT04224701 — First-in-human trial for mitochondrial-derived peptide MOTS-c.
ClinicalTrials.gov — Thymosin beta-4 Phase II cardiac (NCT01311518): https://clinicaltrials.gov/study/NCT01311518 — Phase II trial for TB-500 precursor thymosin beta-4 in cardiac repair.
AHPRA — Medical Board registration standards and prescribing guidance: https://www.ahpra.gov.au/Registration/Registration-Standards.aspx — Practitioner obligations governing peptide prescribing in Australian clinical practice.